T细胞动态、CD8/NK比值与肿瘤生存特征决定骨髓瘤对forimtamig的应答
这项1期研究(NCT04557150)分析GPRC5DxCD3双特异性抗体forimtamig的作用机制与耐药机制,通过深度表型分析、功能T细胞表征、细胞因子释放、sBCMA动力学及MRD评估等生物标志物分析,发现血和骨髓中T/NK细胞比值是应答的强预测因子,肿瘤DNA修复与增殖特征与耐药相关,而T细胞功能障碍特征不预测应答。
要点
- 血和骨髓T/NK细胞比值是forimtamig应答的强预测因子。
- 肿瘤DNA修复与增殖特征是耐药主要标志,T细胞功能障碍特征不预测应答。
- 优化策略包括提升T细胞数量、靶向肿瘤内在耐药机制或个体化给药。
核心结论
- forimtamig治疗优化可通过提升T细胞数量超过NK细胞、靶向肿瘤内在耐药机制或个体化给药实现。
研究设计与样本
- 1期研究(NCT04557150)分析新型GPRC5DxCD3双特异性抗体forimtamig的作用机制与耐药机制。
- 生物标志物分析包括肿瘤和免疫细胞深度表型、功能T细胞表征、细胞因子释放、可溶性BCMA动力学及MRD评估。
- 比较皮下与静脉给药、每周与每4天递增给药、低与高靶剂量对T细胞介导肿瘤杀伤动态的影响。
主要发现
- 机器学习模型显示血和骨髓中T/NK细胞比值是应答的强预测因子。
- 单细胞转录组显示DNA修复和增殖增加是与耐药相关的主要肿瘤特征。
- T细胞功能障碍特征不预测应答,应答与非应答患者T细胞体外杀伤肿瘤能力相当。
- 非应答患者T细胞在体外更高forimtamig暴露下细胞因子释放增加。
临床怎么用
- 可考虑通过提升T细胞数量超过NK细胞来优化forimtamig治疗。
- 可靶向肿瘤内在耐药机制或采用个体化给药策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
T-cell bispecific (TCB) therapies have demonstrated promising therapeutic efficacies for patients with relapsed/refractory multiple myeloma. However, responses are transient and essentially all patients eventually relapse. Cytokine release syndrome and other on-target off-tumor toxicities are common. Together, these challenges ask for new approaches to optimize treatment and to eventually understand resistance mechanisms. This phase 1 study (NCT04557150) investigated mode of action and resistance mechanisms of forimtamig, a novel GPRC5DxCD3 TCB. Biomarker analyses included deep phenotyping of patients' tumor and immune cells, functional T cell characterization, cytokine release, soluble B-cell maturation antigen kinetics and minimal residual disease evaluation. Biomarker data analysis assessed the impact of different TCB treatment approaches on T cell-mediated tumor killing dynamics: subcutaneous vs intravenous administration, weekly vs every 4 days step-up dosing, and low vs high target doses. A machine learning model revealed T-to-natural killer (NK)cell ratio in blood and bone marrow as a strong predictor of response. Single cell transcriptomics showed increased DNA repair and proliferation as major tumor hallmarks associated with resistance, while T cell dysfunction signatures were not predictive of response. T cells from non-responding patients showed an increased cytokine release when exposed to higher forimtamig exposure in an ex vivo setting. T cells from responding and non-responding patients were equally fit in killing tumor cells ex vivo. Our results highlight that forimtamig treatment optimization may be possible by boosting T cell numbers over NK cells, targeting tumor intrinsic resistance mechanisms or individualized dosing approach.
引用
- Dekhtiarenko I, Attig J, Lelios I, et al. T-cell dynamics, CD8/NK ratio and tumor survival hallmarks determine response to T-cell bispecific forimtamig in myeloma. Blood Adv. 2026. PMID: 42747872. doi:10.1182/bloodadvances.2026020503
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。